6 5 MESI affects ~450,000 US patients (~300,000 trial eligible) often reported by etiology (defined autoimmune, idiopathic, surgical, infectious and other) Total ME wAMD- ME DME RVO-ME Other Non- MESI 1 MESI ~5,415 ~1,665 ~1,485 ~1,450 ~360 ~455 ~455K out of 5.4M ME patients in the U.S. may be classified under MESI, ~298K meet KSI-101 trial inclusion U.S. MESI EPIDEMIOLOGY Estimated by two methodologies – method 1 (2025) Thousands of patients 1 Other Non-MESI includes epiretinal membrane ME and RP-associated ME; 2 Non-exhaustive list, other types include laser photocoagulation, DMEK, DSEAK-ME, IOL replacement, scleral buckling, pneumatic retinopexy; 3 Non-exhaustive list, others include birdshot choroidopathy, multiple evanescent white dot syndrome, punctate inner choroidopathy, and more; 4 Non-exhaustive list, others include bartonella sp. Tuberculosis, endophthalmitis; DME = Diabetic Macular Edema; ERM = Epiretinal Membrane; HLA = Human Leukocyte Antigen, ME = Macular Edema; MESI = Macular Edema Secondary to Inflammation; RP = Retinitis Pigmentosa; RVO = Retinal Vein Occlusion; RVO = Retinal Vein Occlusion; UME = Uveitic Macular Edema; wAMD = Wet Age-Related Degeneration POST-SURGICAL ME 2 Pars Plana Vitrectomy ~60K Glaucoma surgery ~50K Cataract surgery ~30K DEFINED AUTOIMMUNE ME 3 HLA-B27 ~20K Multiple sclerosis ~10K Idiopathic Multifocal Choroiditis ~7K Serpiginous choroidopathy ~6K Vogt-Koyanagi-Harada ~4K Ankylosing spondylitis ~15K OTHER MESI Scleritis ~10K Inflammatory CNV ~6K Sarcoidosis ~7K ~145 ~180 ~80 ~20 ~30 MESI Post-Surgical (Acute ~113K) Idiopathic (Etiology unknown)* Defined Autoimmune Related* Other MESI Infectious 4 (Excluded from KSI-101 trials) Post-Surgical (Refractory ~32K) * Other MESI (inflammatory CNV ~6K) * * = KSI-101 PEAK and PINNACLE TRIAL INCLUSION